Melatonin for Sleep: Why It Often Fails—and What to Do Instead to Stay Asleep to Prevent Brain Aging, Cognitive Decline, and Toxin Buildup at Night

“Why do I keep waking up at night after taking melatonin?”

It’s a common question—and a clue that this molecule may not be doing what many assume.

Melatonin is marketed as a sleep solution. But the reality is more complex—and more consequential.

In healthy adults seeking better sleep for cognitive longevity—melatonin’s role is often misunderstood. It’s not a sedative. It doesn’t deepen sleep. And it doesn’t override stress or metabolic noise.

Instead, melatonin works as a circadian signal—a nightly time-stamp that helps align internal rhythms to the light-dark cycle.

This distinction matters. If you’re using melatonin to fix sleep schedule, or thinking about supplementing melatonin for sleep in general, it’s essential to understand what this molecule actually does—and doesn’t do. Especially when sleep “quality” is tightly linked to long-term brain structure, memory consolidation, and neurodegenerative risk.

What follows is not a rejection of melatonin, but a reframe: a deeper look at how—and when—this molecule supports restorative sleep.

And when it may simply be the wrong signal to focus on—and what to optimize instead.

By the end, we’ll also answer the questions that matter most regarding the use of melatonin for sleep:

➔Why do I keep waking up at night after taking melatonin?
➔Does melatonin help you remain asleep?
➔What should you do if you can’t sleep and melatonin doesn’t work?

➤ Section 1: Melatonin for Insomnia & Melatonin to Fix Sleep Schedule (Effects on Sleep Initiation & Sleep Onset Latency)

Melatonin’s primary role in human sleep physiology is not sedative but chronobiotic—meaning it modulates the timing of biological rhythms.

When darkness falls, your pineal gland produces melatonin, telling the suprachiasmatic nucleus (SCN)—your brain’s internal clock—that it’s time to prepare for night. This signaling occurs when melatonin binds to MT1 and MT2 receptors—both of which are G-protein coupled receptors located in the SCN.

Each receptor plays a distinct role: MT1 activation suppresses neuronal firing to promote sleepiness, while MT2 controls phase-shifting—i.e., adjusting the timing of sleep-wake cycles.

Critically, melatonin does not act like traditional sleep aids. Unlike sedative-hypnotic drugs (such as benzodiazepines or Z-drugs), it lacks cortical suppressive activity. Instead, its effect is permissive—lowering the arousal threshold and facilitating sleep initiation when timed correctly.

Therefore, in theory, the optimal time to take melatonin for sleep is about 30 to 60 minutes before DLMO (dim-light melatonin onset)—the point in the evening when your body naturally begins producing melatonin under low-light conditions. This timing allows melatonin to act as a cue for the circadian system, helping to shift or reinforce the sleep phase.

However, this circadian alignment appears to translate into modest practical benefits.

A 2013 meta-analysis of randomized controlled trials, covering a range of primary sleep disorders, found that exogenous melatonin reduced sleep onset latency (SOL)—the time required to transition from full wakefulness to sleep—by an average of 7 minutes compared to placebo. While statistically significant, the magnitude of the benefit of melatonin for sleep was small and highly dependent on baseline circadian status, especially in considering melatonin to fix sleep schedule or melatonin for insomnia.

Still, statistical significance does not always translate into meaningful outcomes—especially for those focused on longevity and brain aging, where the depth and quality of sleep may matter more than small changes in how quickly one falls asleep.

A reduction of 5 to 10 minutes in SOL may be meaningful for individuals with circadian delay or sleep disorders, but it is unlikely to offer perceptible improvement for healthy sleepers or those with sleep maintenance complaints. Moreover, the heterogeneity across study designs, populations, and melatonin formulations (immediate vs. sustained release, dose range from 0.3 mg to 10 mg) complicates direct translation into day-to-day use for the healthy adult in supplementing melatonin for sleep.

In scientific terms, shaving a few minutes off sleep latency likely does little to enhance the glymphatic clearance, REM architecture, or synaptic homeostasis processes most relevant to cognitive aging.

That said, melatonin is used by many different populations—some with normal sleep, others with clinical conditions.

To better understand where it may be most helpful, the 2004 Evidence Report from the U.S. Agency for Healthcare Research and Quality conducted a stratified analysis. Rather than combining results across diverse groups, it separated findings for normal sleepers and those with primary sleep disorders.

Let’s begin with the data from normal, healthy adults.

➤ Section 1.1: Melatonin Use for Adults in Normal Sleepers Without Insomnia

1. In adults classified as normal sleepers—individuals without insomnia or circadian misalignment—exogenous melatonin decreased sleep onset latency (SOL) by approximately 4 minutes compared to placebo. However, the report concluded that “the magnitude of this effect appears to be clinically insignificant.”
2. Melatonin modestly improved sleep efficiency—the proportion of time in bed spent asleep—by a weighted mean difference (WMD) of 2.3% (95% confidence interval: 0.7% to 3.9%). This metric represents the average effect size across studies, accounting for their relative statistical power. ▪️ In daytime sleep, the WMD was 8.0% (CI: 1.0%, 15.0%) ▪️ In nighttime sleep, the WMD dropped to 1.2% (CI: 0%, 2.4%)

WMD reflects the average effect across multiple studies, weighted by study size and precision. In practical terms, a 1-2% gain in sleep efficiency is small and may not be perceptible for most people.

The report emphasized that these effects were minor and potentially inflated by publication bias—noting a disproportionate number of trials reporting positive over null findings.

So far, the takeaway for healthy adults is fairly clear: melatonin offers minimal benefit when no underlying circadian misalignment or sleep disorder is present.

But what about individuals with clinical sleep disruptions?

➤ Section 1.2: Melatonin for Insomnia and Delayed Sleep Phase Disorders in Adults

In contrast, using melatonin for insomnia and other defined sleep disorders showed stronger effects:

1. In adults with any primary sleep disorder, melatonin reduced sleep onset latency (SOL) by 10.7 minutes (95% CI: -17.6, -3.7 min).
2. In Delayed Sleep Phase Syndrome (DSPS)—a circadian rhythm disorder characterized by delayed endogenous melatonin secretion—SOL dropped by 38.8 minutes (95% CI: -50.3 to -27.3) representing the most substantial subgroup response.
3. In individuals with insomnia, melatonin reduced SOL by only 4.3 minutes (95% CI: -8.4, -0.1 min)—this result was statistically insignificant and likely negligible in terms of subjective benefit.

More recent umbrella reviews (e.g., Canadian Journal of Health Technologies, 2022) reinforced these mixed findings.

Some trials showed reductions in SOL; others found no meaningful change. These inconsistencies likely reflect interindividual variability in circadian phase alignment, endogenous melatonin output, and the methodological diversity of melatonin trials.

But study design isn’t the only factor.

Age and circadian biology also influence how the body responds to melatonin.

A dose that barely registers in a 30-year-old may provide modest benefit to someone in their 60s with diminished endogenous output. To see this more clearly, it helps to compare two ends of the physiological curve: young adults with robust melatonin signaling, and older adults with declining nighttime secretion.

Does melatonin improve sleep more in older adults than in the young?

➤ Section 1.3: Why Melatonin Doesn’t Help Sleep in Healthy Young Adults

In young, healthy adults with stable circadian rhythms and intact pineal output, exogenous melatonin offers little benefit when taken at conventional bedtimes. Endogenous secretion is already robust during biological night, and supplemental dosing does not meaningfully reduce sleep latency under these conditions.

This was demonstrated in a tightly controlled 27-day forced desynchrony study involving 36 healthy adults (ages 18 to 30). Participants were placed on a 20-hour sleep-wake cycle in a time-isolated research unit and randomized to receive either a placebo, a physiologic dose (0.3 mg), or a pharmacologic dose (5.0 mg) of melatonin 30 minutes before each scheduled sleep episode.

When sleep was scheduled during the biological day—circadian phases when endogenous melatonin was absent—both melatonin doses improved sleep efficiency from 77% (placebo) to 83%. However, during sleep episodes aligned with the biological night, when endogenous melatonin was naturally present, exogenous melatonin had no additional effect. Sleep efficiency in this condition already averaged 88% without supplementation, and melatonin did not significantly alter sleep latency, slow-wave sleep, REM architecture, or core body temperature.

Table: Effects of Exogenous Melatonin in Healthy Young Adults (Forced Desynchrony Study)

This illustrates that the effects of melatonin for sleep are phase-dependent, not broadly hypnotic.

For young adults without circadian disruption, routine use of melatonin for sleep is unlikely to improve sleep quality or deliver downstream neurocognitive benefit. But in cases of travel or schedule shifts, where circadian alignment is temporarily impaired, targeted use of melatonin to fix sleep schedule may help preserve sleep continuity—and by extension, circadian regulation of metabolic and neural processes.

➤ Section 1.4: Melatonin for Sleep Initiation in Aging Populations

Aging is generally associated with a decline in nocturnal melatonin amplitude, as well as shifts in circadian phase and reduced melatonin receptor sensitivity. In this context, supplementation of melatonin for sleep may help restore circadian signaling, particularly in individuals with diminished endogenous output or age-related circadian misalignment.

In a randomized crossover trial (n = 24, mean age 64.2), participants received placebo, 0.3 mg, or 5.0 mg melatonin under a forced desynchrony protocol. The low dose (0.3 mg) showed a trend toward improved sleep efficiency, primarily during daytime sleep windows. The higher dose (5 mg) increased sleep efficiency during both biological day and night, suggesting dose- and context-dependent efficacy.

However, these findings are not universal.

A larger four-week double blind randomised placebo controlled crossover trial in healthy older adults over 65 years of age with subjective sleep complaints—but no formal insomnia diagnosis—found no measurable benefit from 5 mg melatonin on sleep latency, duration, or efficiency, as assessed via diary, questionnaire, and actigraphy.

Taken together, these studies suggest that melatonin may improve sleep initiation in older adults with documented circadian dysregulation or clear melatonin deficiency. But in those with near-normal rhythms and mild sleep disturbance, melatonin appears insufficient to enhance sleep architecture in a way that would meaningfully impact cognitive aging or overnight neural restoration.

➤ Benefits of Melatonin for Sleep—Conditional, Not Universal

Across populations, melatonin for insomnia or sleep initiation is conditional, not universal. Its strongest utility lies in situations of circadian misalignment—such as shift work, travel, or delayed sleep phase—where it can re-entrain internal rhythms and facilitate timely sleep onset.

In healthy adults with normal circadian timing, the benefit of melatonin for sleep is often negligible. Randomized trials in both young and older cohorts show minimal reductions in sleep onset latency, especially when endogenous melatonin is adequate. Even in older adults—where melatonin output declines—its effects on sleep initiation are inconsistent and often modest, with several trials showing no advantage over placebo.

From a brain aging standpoint, this has direct implications.

Sleep initiation is only one facet of sleep architecture, and not the most relevant for neuroprotection. Longevity-relevant mechanisms—such as glymphatic clearance, hippocampal replay, and REM-linked emotional regulation—depend more on sleep fragmentation, sleep depth and continuity than on how quickly one falls asleep. A 5- to 10-minute reduction in latency, absent downstream benefits, is unlikely to meaningfully affect long-term cognitive resilience.

In this context, melatonin’s role in sleep initiation appears limited in scope for generally healthy, cognitively motivated adults. Its targeted use in circadian misalignment (e.g., melatonin to fix sleep schedule) remains valid—but as a routine intervention for brain-oriented sleep improvement, the evidence does not strongly support melatonin for sleep as a reliable tool.

➤ Section 2: Melatonin to Stay Asleep: Does Melatonin Help With Sleep Continuity

While melatonin can reduce sleep onset latency (SOL) under the right conditions, its effect on maintaining sleep—the benefit to using melatonin to stay asleep—is quite limited.

From a longevity standpoint, this distinction is critical.

Initiating sleep is only the beginning of sleep-dependent neural repair; the true cognitive dividends of sleep occur in its continuity—especially during slow-wave sleep (SWS) and REM, which consolidate memory, regulate emotion, and clear neurotoxic waste.

Melatonin’s limitations here are primarily pharmacokinetic—relating to how the body processes the compound. Standard oral melatonin has a short elimination half-life (20–50 minutes), meaning plasma concentrations peak rapidly but also decline within a few hours. By the second half of the night, exogenous melatonin is largely absent from circulation. This undermines its ability to support sleep consolidation, defined as the uninterrupted progression through full sleep cycles.

In a 2013 meta-analysis (Ferracioli-Oda et al.), total sleep time (TST) increased by just ~8 minutes versus placebo.

While statistically significant, such a marginal extension in the use of melatonin for sleep is unlikely to translate into meaningful cognitive or physiological benefit—particularly in aging adults seeking neuroprotective sleep architecture.

Similarly, in the 2004 AHRQ Evidence Report, melatonin demonstrated no consistent benefit for wakefulness after sleep onset (WASO), number of nighttime awakenings, or overall sleep continuity in healthy sleepers. These are the very disruptions that compromise glymphatic flow and reduce sleep’s restorative efficiency.

Even in trials where melatonin improved initial sleep timing, it failed to extend sleep duration or prevent mid-sleep arousals. This pharmacological ceiling limits its relevance for preserving sleep structure—particularly in the second half of the night, where REM predominates and synaptic plasticity processes peak.

➤ Melatonin to Stay Asleep: Older Adults with Insomnia

A partial exception may exist in older adults with chronic insomnia—a group often characterized by reduced nighttime melatonin output and altered circadian regulation.

A 2022 meta-analysis by Marupuru et al., which synthesized findings from 17 clinical trials evaluating melatonin for sleep in adults aged 55 and older with chronic insomnia, reported the following outcomes:

▪️ Objective TST (total sleep time) increased by ~21 minutes

▪️ Objective SOL (sleep onset latency) reduced by ~13.8 minutes

▪️ Subjective SOL (sleep onset latency) reduced by ~8.3 minutes

▪️ Sleep efficiency—the percentage of time spent asleep while in bed—showed no statistically significant improvement

Despite these modest benefits, the unchanged sleep efficiency suggests that melatonin does not meaningfully reduce sleep fragmentation, even in aging adults with endogenous melatonin deficiency.

From a brain aging standpoint, this narrows the potential role of melatonin for sleep: while it may support sleep initiation and modestly extend duration in older individuals with insomnia, it does not appear to enhance the sleep continuity needed to protect overnight neural repair.

➤ Brain Aging: Melatonin to Stay Asleep—Limited Use Beyond Sleep Initiation

Melatonin’s short half-life and narrow pharmacodynamic window (its duration of biological activity) make it ill-suited for sustaining continuous, architecture-rich sleep—a key reason why using melatonin to stay asleep often disappoints. For individuals aiming to protect long-term brain function, uninterrupted, deep-stage sleep is essential—not just faster onset. While older adults with circadian disruption may derive modest benefit from prolonged-release versions, the overall effect size remains small.

In practical terms: for individuals experiencing early morning awakenings, sleep fragmentation, or disrupted REM sleep, taking melatonin to stay asleep is not an adequate solution.

As a tool for cognitive longevity, melatonin’s role in sleep maintenance is weak. For a deeper dive into how fragmented sleep accelerates brain aging—and what sleep architecture really protects your cortex—see: The 3 Forms of Sleep Disruption That Shrink Your Brain.

➤ Section 3: What Melatonin Does NOT Do for Sleep

Melatonin is frequently mischaracterized as a broad-spectrum sleep aid, when in fact its pharmacological actions are narrow and circadian-specific. It is more accurately classified as a chronobiotic—a compound that adjusts the phase of biological rhythms—rather than a hypnotic, which directly induces or deepens sleep.

Here are key points about what melatonin does not do for sleep in healthy (non-jetlagged, non-shift-work) individuals:

➤ Melatonin Does Not Sedate or Suppress Stress

Melatonin does not induce sedation in the pharmacodynamic sense. Unlike GABAergic agents (e.g., benzodiazepines, Z-drugs), melatonin does not inhibit central nervous system activity or promote widespread neuronal quiescence. Its mechanism is circadian gating—facilitating sleep readiness via MT1/MT2 receptor signaling—but it cannot override heightened arousal states driven by stress, cortisol, sympathetic activation, or stimulant use.

As a result, melatonin has no capacity to counteract acute arousal.

Elevated evening cortisol, unresolved stress, or stimulants like caffeine will override the effects of melatonin. If the brain is still metabolically or emotionally activated at bedtime, melatonin is unlikely to induce sleep—because it’s not designed to.

➤ Melatonin Does Not Meaningfully Increase Sleep Duration

Meta-analyses consistently report minimal increases in total sleep time (TST) with supplemental melatonin for sleep. As noted in Section 2, the average gain in TST is approximately 8 to 21 minutes, depending on population and formulation.

This is not sufficient to restore chronic sleep debt or extend physiologic recovery windows.

Unlike pharmacologic agents that can prolong slow wave sleep (SWS) or suppress arousals for hours, melatonin does not augment homeostatic sleep pressure—it cannot convert a 5-hour sleeper into an 8-hour sleeper, nor does it “add” hours of sleep in individuals who already achieve physiologic sleep duration.

➤ Melatonin Does Not Improve Sleep Maintenance or Prevent Sleep Fragmentation

Melatonin generally fails to prevent nocturnal awakenings or reduce wakefulness after sleep onset (WASO) in controlled trials. Across multiple studies and meta-analyses, there is little evidence that melatonin improves sleep continuity, except potentially in circadian misalignment contexts or in older adults using extended-release forms.

Given that sleep fragmentation disrupts glymphatic clearance, impairs REM integrity, and accelerates cognitive decline in aging populations, this limitation is not trivial. The ability to stay asleep—especially during the second half of the night—is where most neurorestorative sleep unfolds.

Melatonin does not support this process.

➤ Melatonin Does Not Enhance REM or Deep Sleep Architecture

Melatonin does not increase the proportion of REM or N3 (slow-wave) sleep. If anything, exogenous melatonin can delay the onset of REM sleep, especially when taken at suboptimal circadian phases.

Polysomnographic studies have shown no consistent enhancement in sleep stage depth, duration, or transitions. The widely held belief that melatonin improves “sleep quality” lacks empirical support in adults with intact circadian function.

For those aiming to preserve memory consolidation, synaptic downscaling, and emotional processing overnight, melatonin is not the mechanism to target. These processes depend on intact sleep architecture—not just timely initiation.

➤ Brain Longevity: The Limitations of Supplementing Melatonin For Sleep

The benefit of using melatonin for sleep lies in its role as a circadian signal—not as a builder of sleep depth or continuity.

It does not sedate, does not consolidate, and does not deepen sleep in a way that supports long-term brain health. Its utility lies in correcting timing mismatches—such as jet lag or delayed sleep phase—not in remodeling sleep structure, helping you stay asleep or sustaining the stages critical to neuroprotection.

For cognitively intact adults focused on brain longevity, the case for melatonin is narrow: it helps align internal rhythms to external cues. But once alignment is achieved, the quality, depth, and stability of sleep must be supported through other pathways—behavioral, metabolic, and neurophysiologic—not through circadian signaling alone.

➤ Section 4: Should You Take Melatonin For Sleep? Evaluate the Signal Before the Supplement

If you’re healthy, not jet-lagged, and don’t struggle to fall asleep—taking melatonin for sleep is unlikely to help you enjoy better quality sleep. It won’t deepen your sleep, extend it meaningfully, or prevent the types of awakenings that fragment rest and accelerate brain aging.

But dismissing melatonin altogether also misses something more important:

It’s not a weak sleep aid. It’s a strong signal—circadian, metabolic, mitochondrial—and strong signals, misapplied, can misfire.

Beyond Melatonin for Sleep: The Double-Edged Biology of Melatonin: Melatonin’s Pleiotropic Reach Cuts Both Ways

Melatonin isn’t just the “sleep hormone.”

It’s a multisystem molecule, with receptor sites throughout the brain, endocrine axis, and immune system. That widespread presence explains why it’s gaining traction as a longevity candidate—but it also means supplementation can have consequences far beyond sleep.

▪️ It exerts potent antioxidant and anti-inflammatory effects, particularly in mitochondria. Melatonin scavenges reactive oxygen and nitrogen species, upregulates antioxidant enzymes, chelates transition metals, and helps preserve mitochondrial function under stress.

This profile positions melatonin as a mitochondria-targeted antioxidant—a role with real therapeutic promise for neurodegeneration and cellular aging.

But melatonin’s influence doesn’t stop there—and not all downstream effects are beneficial:

▪️ It impairs glucose tolerance in both healthy individuals and those with type 2 diabetes.

▪️ It modulates reproductive hormones, including LH and FSH, and may reduce sperm quality.

▪️ Evidence suggests it inhibits hippocampal long-term potentiation, a core mechanism in memory formation.

▪️ It produces unpredictable effects on REM sleep, altering its onset or proportion depending on dose, receptor subtype, and timing.

In other words: melatonin is not harmless. It’s powerful—biochemically, hormonally, and neurologically. And powerful tools demand precise context and intent.

Why Measuring Melatonin First Makes More Sense

If melatonin exerts both protective and disruptive effects—context becomes everything.

Before supplementing, a foundational question must be asked:

Is this signal even deficient, and if so, when?

Single-timepoint melatonin tests—especially at bedtime—offer incomplete insight. Melatonin is a circadian signal, not a static hormone. To evaluate it accurately, you need to see the full curve.

A 4-point salivary melatonin profile—with samples taken in the morning, noon, evening, and night—reveals how your internal clock ramps up and down over 24 hours.

Here’s how that pattern typically appears in healthy individuals:

▪️ Morning: Suppressed—typically <3 pg/mL by 7–9 a.m.

▪️ Noon: Flat—usually <2 pg/mL during peak daylight hours

▪️ Evening: Rising—beginning after sunset, ideally 10–20 pg/mL

▪️ Night (2–4 a.m.): Peak levels of 20–70 pg/mL in adults with intact pineal output

A blunted curve—with low night levels—or a delayed rise in evening secretion may indicate circadian misalignment, pineal insufficiency, or light-at-night suppression.

In contrast, if the entire curve is intact and properly timed, then melatonin is not the problem—and adding more may distort the rhythm, not enhance it.

The Ayumetrix 4-point Melatonin Panel captures your full circadian melatonin rhythm—morning, noon, evening, and night—to reveal whether melatonin is rising at the right time, peaking overnight, or failing to signal effectively. This dynamic view is essential for determining whether supplementation is warranted—or misaligned.

When nocturnal melatonin is low—or the curve is delayed—strategic, low-dose intervention may be appropriate.

This is particularly relevant in:

▪️ Older adults, where endogenous secretion declines with age

▪️ Shift workers, whose light exposure desynchronizes melatonin timing

▪️ Individuals with circadian rhythm disorders, such as DSPS (Delayed Sleep Phase Syndrome)

In some cases, timed melatonin may restore rhythm, improve sleep initiation, and provide mitochondrial antioxidant support without overwhelming the system.

However, if melatonin is already sufficient—particularly with a robust nocturnal rise and low daytime baseline—adding more introduces pharmacologic distortion. You are layering an exogenous rhythm onto an endogenous signal that is already intact.

This can dysregulate:

▪️ Glucose tolerance, especially with daytime or high-dose evening use

▪️ REM architecture, shifting its onset or expression

▪️ Neuroplasticity, through suppression of hippocampal long-term potentiation

▪️ Reproductive signaling, via effects on gonadotropins and sex hormone pathways

Melatonin is not inert. Its effects extend across metabolic, neural, and endocrine systems—and in individuals with an intact circadian profile, supplementation of melatonin for sleep may disrupt more than it stabilizes.

This is why measurement precedes intervention. Without confirming a true deficit, supplementation of melatonin for sleep is not personalized longevity roadmapping—it’s speculation.

In the context of cognitive longevity and sleep integrity, mapping the rhythm—before you use melatonin for sleep— is more valuable than assuming the gap.

A Better Question: If Melatonin Isn’t the Problem, What Is?

When sleep becomes fragmented or non-restorative, melatonin is often blamed—or reflexively supplemented.

But if melatonin levels test normal—or if age, lifestyle, and dosing timing all suggest endogenous production is intact—then persistent sleep issues likely originate elsewhere.

In many such cases, melatonin isn’t the missing piece.

It’s the signal that’s being suppressed—or overridden.

One of the most common upstream disruptors is cortisol—a glucocorticoid hormone that, when elevated in the evening or overnight, can delay sleep onset, fragment REM cycles, and directly inhibit melatonin synthesis at the pineal level.

Even when melatonin secretion appears statistically “normal,” its effects may be undermined—either by being mistimed relative to circadian phase, or by being drowned out by elevated cortisol and downstream HPA axis activation.

To detect this, a single cortisol reading isn’t enough. Cortisol is a circadian hormone—what matters is the shape of the curve, not just one time point.

A 4-point salivary cortisol profile—collected in the morning, noon, evening, and night—reveals how your internal stress rhythm activates and winds down over 24 hours.

Here’s how that pattern typically appears in healthy individuals:

▪️ Morning (6–8 a.m.): Peak levels—6 to 10 ng/mL, providing the “get-up-and-go” signal

▪️ Noon: Moderate—2 to 4 ng/mL, tapering naturally

▪️ Evening: Low—1 to 2 ng/mL, supporting calm and metabolic wind-down

▪️ Night (10 p.m. to 12 a.m.): Minimal—<1 ng/mL, to allow melatonin to rise

Deviations from this curve—like flat mornings, slow declines, or elevated nights—can fragment sleep, block melatonin, and increase overnight arousals.

If sleep feels misaligned and melatonin didn’t help, the Adrenal Stress Profile or Diurnal Cortisol test can show whether your cortisol rhythm is driving the disconnect.

These patterns aren’t random—and once identified, they often point to modifiable inputs: behavior, environment, or metabolic load.

Specifically, evening or nighttime elevations often reflect:

▪️ Environmental stressors, including light exposure, irregular eating patterns, or noise

▪️ Psychological activation, such as unresolved cognitive arousal or latent emotional stress

▪️ Physiologic stress, including glycemic volatility, inflammation, or overtraining, hypoxia (from sleep apnea)

When cortisol is dysregulated, using melatonin to initiate or reschedule sleep targets the symptom, not the signal.

If cortisol remains elevated, the circadian system cannot consolidate sleep, regardless of exogenous melatonin levels.

This is why testing matters. Without assessing upstream drivers, taking melatonin for sleep becomes a misapplied tool—delivered out of sequence, and often in vain.

If you’d rather understand the full context before measuring, that’s reasonable. But in cases where sleep remains disrupted despite good habits, data often answers what theory can’t.

In any case, that’s where we’re headed next: a deeper look at cortisol as the leading domino in the sleep-wake cascade. We’ll also revisit melatonin from a broader lens—its role not as a sleep molecule, but as a bioenergetic signal with potential (and pitfalls) for aging & longevity.

Melatonin isn’t a default fix—it’s a targeted tool.

And like any tool, it works best when there’s a clear indication.

Test first. Then decide.

Because in the pursuit of cognitive longevity, the trend of the signal matters more than the signal itself.

What Happens Next? Beyond Melatonin for Sleep: How I Evaluate Melatonin’s Broader Effects, When I Measure Cortisol, and What I Actually Do to Support Sleep Architecture

This discussion sets the stage for the next two articles:

1. Melatonin’s pleiotropic impact—where we’ll unpack the balance of antioxidant, metabolic, endocrine, and neural effects, and why these consequences matter for longevity.
2. Cortisol as the upstream disruptor—a deep dive into how elevated evening and nighttime cortisol undermines both sleep and melatonin signaling, and why measuring cortisol (not adding melatonin for sleep) can be a more effective place to start.
3. What I do—how I evaluate melatonin rhythms, decide when (and whether) to supplement melatonin for sleep or longevity, screen for cortisol dominance, and support sleep architecture through non-supplemental strategies.

FAQ

References

• Rubio-Sastre P, Scheer FA, Gómez-Abellán P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014 Oct 1;37(10):1715-9. doi: 10.5665/sleep.4088. PMID: 25197811; PMCID: PMC4173928.
• Candyce Hamel, Jennifer Horton, CADTH Health Technology Review, Melatonin for the Treatment of Insomnia: A 2022 Update 3
• Givler D, Givler A, Luther PM, Wenger DM, Ahmadzadeh S, Shekoohi S, Edinoff AN, Dorius BK, Jean Baptiste C, Cornett EM, Kaye AM, Kaye AD. Chronic Administration of Melatonin: Physiological and Clinical Considerations. Neurol Int. 2023 Mar 15;15(1):518-533. doi: 10.3390/neurolint15010031. PMID: 36976674; PMCID: PMC10053496.
• Tuft C, Matar E, Menczel Schrire Z, Grunstein RR, Yee BJ, Hoyos CM. Current Insights into the Risks of Using Melatonin as a Treatment for Sleep Disorders in Older Adults. Clin Interv Aging. 2023 Jan 12;18:49-59. doi: 10.2147/CIA.S361519. PMID: 36660543; PMCID: PMC9842516.
• Gobbi G, Comai S. Differential Function of Melatonin MT1 and MT2 Receptors in REM and NREM Sleep. Front Endocrinol (Lausanne). 2019 Mar 1;10:87. doi: 10.3389/fendo.2019.00087. PMID: 30881340; PMCID: PMC6407453.
• Baskett JJ, Broad JB, Wood PC, Duncan JR, Pledger MJ, English J, Arendt J. Does melatonin improve sleep in older people? A randomised crossover trial. Age Ageing. 2003 Mar;32(2):164-70. doi: 10.1093/ageing/32.2.164. PMID: 12615559.
• SMYTHE, G., LAZARUS, L. Growth Hormone Regulation by Melatonin and Serotonin. Nature 244, 230–231 (1973). https://doi.org/10.1038/244230a0
• Duffy JF, Wang W, Ronda JM, Czeisler CA. High dose melatonin increases sleep duration during nighttime and daytime sleep episodes in older adults. J Pineal Res. 2022 Aug;73(1):e12801. doi: 10.1111/jpi.12801. Epub 2022 May 13. PMID: 35436355; PMCID: PMC9288519.
• Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl. 2002 Jul-Aug;23(4):572-8. PMID: 12065466.
• Buscemi N, Vandermeer B, Pandya R, Hooton N, Tjosvold L, Hartling L, Baker G, Vohra S, Klassen T. Melatonin for Treatment of Sleep Disorders. Evidence Report/Technology Assessment No. 108. (Prepared by the University of Alberta Evidence-based Practice Center, under Contract No. 290-02-0023.) AHRQ Publication No. 05-E002-2. Rockville, MD: Agency for Healthcare Research and Quality. November 2004.
• Wang LM, Suthana NA, Chaudhury D, Weaver DR, Colwell CS. Melatonin inhibits hippocampal long-term potentiation. Eur J Neurosci. 2005 Nov;22(9):2231-7. doi: 10.1111/j.1460-9568.2005.04408.x. PMID: 16262661; PMCID: PMC2581482.
• Valcavi R, Zini M, Maestroni GJ, Conti A, Portioli I. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone. Clin Endocrinol (Oxf). 1993 Aug;39(2):193-9. doi: 10.1111/j.1365-2265.1993.tb01773.x. PMID: 8370132.
• Comai S, Gobbi G. Melatonin, Melatonin Receptors and Sleep: Moving Beyond Traditional Views. J Pineal Res. 2024 Oct;76(7):e13011. doi: 10.1111/jpi.13011. PMID: 39400423.
• Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773. doi: 10.1371/journal.pone.0063773. PMID: 23691095; PMCID: PMC3656905.
• Lelak K, Vohra V, Neuman MI, Toce MS, Sethuraman U. Pediatric Melatonin Ingestions – United States, 2012-2021. MMWR Morb Mortal Wkly Rep. 2022 Jun 3;71(22):725-729. doi: 10.15585/mmwr.mm7122a1. Erratum in: MMWR Morb Mortal Wkly Rep. 2022 Jul 08;71(27):885. doi: 10.15585/mmwr.mm7127a4. PMID: 35653284; PMCID: PMC9169525.
• Menczel Schrire Z, Phillips CL, Chapman JL, Duffy SL, Wong G, D’Rozario AL, Comas M, Raisin I, Saini B, Gordon CJ, McKinnon AC, Naismith SL, Marshall NS, Grunstein RR, Hoyos CM. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis. J Pineal Res. 2022 Mar;72(2):e12782. doi: 10.1111/jpi.12782. Epub 2021 Dec 30. PMID: 34923676.
• Wyatt JK, Dijk DJ, Ritz-de Cecco A, Ronda JM, Czeisler CA. Sleep-facilitating effect of exogenous melatonin in healthy young men and women is circadian-phase dependent. Sleep. 2006 May;29(5):609-18. doi: 10.1093/sleep/29.5.609. PMID: 16774150.
• Lauritzen ES, Kampmann U, Pedersen MGB, Christensen LL, Jessen N, Møller N, Støy J. Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial. J Pineal Res. 2022 Aug;73(1):e12809. doi: 10.1111/jpi.12809. Epub 2022 Jun 9. PMID: 35619221; PMCID: PMC9540532.
• Marupuru S, Arku D, Campbell AM, Slack MK, Lee JK. Use of Melatonin and/on Ramelteon for the Treatment of Insomnia in Older Adults: A Systematic Review and Meta-Analysis. J Clin Med. 2022 Aug 31;11(17):5138. doi: 10.3390/jcm11175138. PMID: 36079069; PMCID: PMC9456584.